The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

BTOG 2021 | NERO trial: PARP inhibitors for chemosensitive NSCLC

Name: NERO trial: PARP inhibitors for chemosensitive NSCLC
Uploaded: 2021-04-19T00:00:00Z
Duration: 59 s
Description: Dean Fennell, PhD, FRCP, University Hospitals of Leicester NHS Trust, Leicester, UK, shares an update on the randomized Phase II/III NERO study (NCT01788332) investigating PARP inhibitors in patients with non-small cell lung cancer (NSCLC) who have previously responded to chemotherapy. This interview took place during the 19th British Thoracic Oncology Group (BTOG) Annual Conference 2021.

Dean Fennell • 19 Apr 2021

BTOG 2021

Lung Cancer Non-Small Cell Lung Cancer Olaparib

NERO

Dean Fennell, PhD, FRCP, University Hospitals of Leicester NHS Trust, Leicester, UK, shares an update on the randomized Phase II/III NERO study (NCT01788332) investigating PARP inhibitors in patients with non-small cell lung cancer (NSCLC) who have previously responded to chemotherapy. This interview took place during the 19th British Thoracic Oncology Group (BTOG) Annual Conference 2021.